In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
Ilaria Iacobucci(St. Jude Children's Research Hospital), Giovanni Martinelli(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Silvia Pomella(University of Rome Tor Vergata), Annalisa Lonetti(University of Bologna), Domenico Russo, Stefano Pileri(European Institute of Oncology), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Pier Giuseppe Pelicci(Office of Technology Transfer), Federica Cattina(University of Brescia), Viviana Guadagnuolo(University of Bologna), Simona Righi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Enrica Imbrogno(University of Bologna), Maria Vittoria Verga Falzacappa(University of Trieste), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Claudio Agostinelli, Claudia Venturi(University of Bologna), Antonella Vitale(University of the Sacred Heart), Enrico Derenzini(University of Milan), Loredana Elia(Sapienza University of Rome), Anna Ferrari(University of Bologna)
Cited by 28
Related Papers
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
|Nature reviews. Cancer|2006|2.2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
|Cell|1992|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k